What is she best known for?
The fields of study she is best known for:
Pharmacology, Cancer cell, P-glycoprotein, Doxorubicin and Biochemistry are her primary areas of study.
Her work carried out in the field of Pharmacology brings together such families of science as Cell culture, ATP-binding cassette transporter, Drug delivery, Efflux and Nanoparticles for drug delivery to the brain.
Her Cancer cell research includes themes of Cancer research and Immunology.
Her Cancer research research integrates issues from Gene silencing, Kinase, Programmed cell death and Cell growth.
The study incorporates disciplines such as Cell, Thapsigargin and Calmodulin in addition to P-glycoprotein.
Her Doxorubicin study which covers Cytotoxic T cell that intersects with HT29 Cells.
Her most cited work include:
- Consensus guidelines for the detection of immunogenic cell death (449 citations)
- The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. (228 citations)
- Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. (207 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Cancer research, Doxorubicin, Pharmacology, Biochemistry and P-glycoprotein.
Her study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Multiple drug resistance, Chronic lymphocytic leukemia and Immune system.
Chiara Riganti has researched Cancer cell in several fields, including Cell, Mitochondrion, Cell biology and Cell growth.
As a part of the same scientific family, Chiara Riganti mostly works in the field of Doxorubicin, focusing on Cytotoxicity and, on occasion, Cytotoxic T cell.
Chiara Riganti focuses mostly in the field of Pharmacology, narrowing it down to topics relating to In vitro and, in certain cases, In vivo and Solid lipid nanoparticle.
She interconnects Efflux and Stem cell in the investigation of issues within P-glycoprotein.
She most often published in these fields:
- Cancer research (38.77%)
- Doxorubicin (21.38%)
- Pharmacology (20.65%)
What were the highlights of her more recent work (between 2019-2021)?
- Cancer research (38.77%)
- Cancer cell (14.13%)
- Doxorubicin (21.38%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Cancer cell, Doxorubicin, Cell biology and Multiple drug resistance.
Her Cancer research research incorporates elements of Mitochondrion, Immune system, Cisplatin and Cytotoxicity.
Her Cancer cell research is mostly focused on the topic Immunogenic cell death.
Her studies deal with areas such as Osteosarcoma, P-glycoprotein, Nanoparticle, Biophysics and Pharmacology as well as Doxorubicin.
The various areas that Chiara Riganti examines in her Pharmacology study include Dialysis, Nitric oxide, Anthracycline and Peritoneal dialysis.
Her Multiple drug resistance study integrates concerns from other disciplines, such as Liposome, Intracellular and ATP-binding cassette transporter.
Between 2019 and 2021, her most popular works were:
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (106 citations)
- Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. (26 citations)
- Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma (23 citations)
In her most recent research, the most cited papers focused on:
Chiara Riganti mostly deals with Doxorubicin, Cancer research, Multiple drug resistance, P-glycoprotein and Intracellular.
Chiara Riganti has included themes like Osteosarcoma, Nitric oxide, Cytotoxicity, Breast cancer and Pediatric cancer in her Doxorubicin study.
Her Cancer research research also works with subjects such as
- Protein kinase B which intersects with area such as RHOA, Leukemia, Cytotoxic T cell and Chronic lymphocytic leukemia,
- PI3K/AKT/mTOR pathway that connect with fields like ABCA1, Tumor microenvironment and Stromal cell.
Her Multiple drug resistance research incorporates themes from Nanoparticle and Biophysics.
Her work deals with themes such as Triple-negative breast cancer, Calreticulin and Pharmacology, which intersect with P-glycoprotein.
Her work focuses on many connections between Intracellular and other disciplines, such as Cancer cell, that overlap with her field of interest in Signal transduction, Tumor progression, Cell biology and Mutant.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
